Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
29
pubmed:dateCreated
2010-10-8
pubmed:abstractText
The primary objective of this study was to confirm the efficacy of romidepsin in patients with treatment refractory cutaneous T-cell lymphoma (CTCL).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1527-7755
pubmed:author
pubmed:issnType
Electronic
pubmed:day
10
pubmed:volume
28
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
4485-91
pubmed:meshHeading
pubmed-meshheading:20697094-Aged, pubmed-meshheading:20697094-Antibiotics, Antineoplastic, pubmed-meshheading:20697094-Asthenia, pubmed-meshheading:20697094-Depsipeptides, pubmed-meshheading:20697094-Drug Administration Schedule, pubmed-meshheading:20697094-Drug Resistance, Neoplasm, pubmed-meshheading:20697094-Female, pubmed-meshheading:20697094-Humans, pubmed-meshheading:20697094-Infusions, Intravenous, pubmed-meshheading:20697094-Lymphoma, T-Cell, Cutaneous, pubmed-meshheading:20697094-Male, pubmed-meshheading:20697094-Middle Aged, pubmed-meshheading:20697094-Nausea, pubmed-meshheading:20697094-Neoplasm Staging, pubmed-meshheading:20697094-Prospective Studies, pubmed-meshheading:20697094-Skin, pubmed-meshheading:20697094-Skin Neoplasms, pubmed-meshheading:20697094-Treatment Outcome, pubmed-meshheading:20697094-Vomiting
pubmed:year
2010
pubmed:articleTitle
Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma.
pubmed:affiliation
Guy's and St Thomas' National Health Service Foundation Trust, London, United Kingdom. sean.whittaker@kcl.ac.uk
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase II